CD79A and infection: Extensive post-hoc analyses of the RV144 trial generated two correlates; antibodies to Env V1/V2 scaffolded protein correlated with reduced infection risk, whereas the levels of monomeric IgA Env-specific binding antibodies correlated with increased risk.